Johnson & Johnson's ICOTYDE meets primary endpoint in Phase 3 psoriatic arthritis trial
JNJ•Johnson & Johnson said its Phase 3 trial of once-daily oral ICOTYDE met its primary endpoint, showing significant improvement in joint disease activity versus placebo at Week 16.
1. Trial results
The trial involved biologic-naive adults with active psoriatic arthritis. Joint and skin responses improved further through Week 24, and no new safety signals were identified. Results are being presented at the American College of Rheumatology Convergence 2026. ICOTYDE treats plaque psoriasis in the U.S. but is not approved for psoriatic arthritis.
